{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Anti-TNF&page=8",
    "query": {
      "intervention": "Anti-TNF",
      "page": 8
    },
    "page_size": 10
  },
  "pagination": {
    "page": 8,
    "page_size": 10,
    "total_count": 183,
    "total_pages": 19,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Anti-TNF&page=9&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Anti-TNF&page=7&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-14T22:55:10.495Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00829595",
      "title": "Pneumococcal Vaccination in Patients With Inflammatory Bowel Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Inflammatory Bowel Disease",
        "Crohn Disease",
        "Ulcerative Colitis"
      ],
      "interventions": [
        {
          "name": "23-valent polysaccharide pneumococcal vaccine (Pneumovax TM)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Cedars-Sinai Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 69,
      "start_date": "2005-05",
      "completion_date": "2007-12",
      "has_results": false,
      "last_update_posted_date": "2009-01-27",
      "last_synced_at": "2026-11-14T22:55:10.495Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00829595"
    },
    {
      "nct_id": "NCT00792233",
      "title": "Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Juvenile Idiopathic Arthritis"
      ],
      "interventions": [
        {
          "name": "Withdrawal of anti-TNF therapy",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Children's Hospital Medical Center, Cincinnati",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "20 Years",
        "sex": "ALL",
        "summary": "4 Years to 20 Years"
      },
      "enrollment_count": 137,
      "start_date": "2009-06",
      "completion_date": "2015-10",
      "has_results": false,
      "last_update_posted_date": "2016-04-15",
      "last_synced_at": "2026-11-14T22:55:10.495Z",
      "location_count": 16,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 13 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00792233"
    },
    {
      "nct_id": "NCT01077362",
      "title": "A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Arthritis, Psoriatic"
      ],
      "interventions": [
        {
          "name": "placebo",
          "type": "DRUG"
        },
        {
          "name": "ustekinumab 45 mg",
          "type": "DRUG"
        },
        {
          "name": "ustekinumab 90 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 312,
      "start_date": "2010-03",
      "completion_date": "2012-11",
      "has_results": true,
      "last_update_posted_date": "2014-02-27",
      "last_synced_at": "2026-11-14T22:55:10.495Z",
      "location_count": 25,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Los Angeles, California + 22 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01077362"
    },
    {
      "nct_id": "NCT03591770",
      "title": "Shingrix Vaccine in Patients With Moderate to Severe Ulcerative Colitis on Tofacitinib",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Inflammatory Bowel Diseases"
      ],
      "interventions": [
        {
          "name": "SHINGRIX",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Boston Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2019-07-31",
      "completion_date": "2024-07-04",
      "has_results": true,
      "last_update_posted_date": "2025-02-21",
      "last_synced_at": "2026-11-14T22:55:10.495Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03591770"
    },
    {
      "nct_id": "NCT05889182",
      "title": "A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hidradenitis Suppurativa"
      ],
      "interventions": [
        {
          "name": "Upadacitinib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 1328,
      "start_date": "2023-06-21",
      "completion_date": "2028-08",
      "has_results": false,
      "last_update_posted_date": "2026-11-13",
      "last_synced_at": "2026-11-14T22:55:10.495Z",
      "location_count": 87,
      "location_summary": "Birmingham, Alabama • Fountain Hills, Arizona • Phoenix, Arizona + 73 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fountain Hills",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05889182"
    },
    {
      "nct_id": "NCT05014555",
      "title": "Sustained Humoral and Cell-Mediated Immunogenicity of COVID-19 Vaccines in Patients With Inflammatory Bowel Disease",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Inflammatory Bowel Diseases"
      ],
      "interventions": [
        {
          "name": "COVID-19 Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GI Alliance",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 400,
      "start_date": "2023-07-05",
      "completion_date": "2024-01",
      "has_results": false,
      "last_update_posted_date": "2023-06-18",
      "last_synced_at": "2026-11-14T22:55:10.495Z",
      "location_count": 4,
      "location_summary": "Jacksonville, Florida • Baton Rouge, Louisiana • Southlake, Texas + 1 more",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Baton Rouge",
          "state": "Louisiana"
        },
        {
          "city": "Southlake",
          "state": "Texas"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05014555"
    },
    {
      "nct_id": "NCT00468546",
      "title": "A Study to Evaluate the Safety and Efficacy of MabThera (Rituximab) in Combination With Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Who Failed on Anti-Tumor Necrosis Factor Alpha Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "MabThera/Rituxan",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 520,
      "start_date": "2003-05",
      "completion_date": "2012-07",
      "has_results": true,
      "last_update_posted_date": "2016-10-25",
      "last_synced_at": "2026-11-14T22:55:10.495Z",
      "location_count": 67,
      "location_summary": "Birmingham, Alabama • Mesa, Arizona • Paradise Valley, Arizona + 54 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Paradise Valley",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00468546"
    },
    {
      "nct_id": "NCT02632175",
      "title": "Long-term Safety and Efficacy Study of Adalimumab in Pediatric Subjects With Ulcerative Colitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Ulcerative Colitis"
      ],
      "interventions": [
        {
          "name": "Adalimumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "4 Years to 17 Years"
      },
      "enrollment_count": 59,
      "start_date": "2015-11-26",
      "completion_date": "2025-04-08",
      "has_results": true,
      "last_update_posted_date": "2025-10-16",
      "last_synced_at": "2026-11-14T22:55:10.495Z",
      "location_count": 4,
      "location_summary": "Orlando, Florida • Minneapolis, Minnesota • Rochester, Minnesota + 1 more",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Tacoma",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02632175"
    },
    {
      "nct_id": "NCT03049449",
      "title": "T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoma, Large-Cell, Anaplastic",
        "Enteropathy-Associated T-Cell Lymphoma",
        "Lymphoma, Large B-Cell, Diffuse",
        "Lymphoma, Extranodal NK-T-Cell",
        "Lymphoma, T-Cell, Peripheral"
      ],
      "interventions": [
        {
          "name": "Anti-Tumor Necrosis Factor (TNF) Receptor Superfamily Member 8 (CD30) Chimeric Antigen Receptor (CAR) T cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "73 Years",
        "sex": "ALL",
        "summary": "18 Years to 73 Years"
      },
      "enrollment_count": 26,
      "start_date": "2017-03-17",
      "completion_date": "2022-01-26",
      "has_results": true,
      "last_update_posted_date": "2023-01-18",
      "last_synced_at": "2026-11-14T22:55:10.495Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03049449"
    },
    {
      "nct_id": "NCT00217386",
      "title": "Anti-Thymocyte Globulin and Etanercept in Treating Patients With Myelodysplastic Syndromes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia",
        "Myelodysplastic Syndromes",
        "Myelodysplastic/Myeloproliferative Diseases"
      ],
      "interventions": [
        {
          "name": "anti-thymocyte globulin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "etanercept",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2004-03",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2010-09-15",
      "last_synced_at": "2026-11-14T22:55:10.495Z",
      "location_count": 4,
      "location_summary": "Bellingham, Washington • Port Angeles, Washington • Seattle, Washington",
      "locations": [
        {
          "city": "Bellingham",
          "state": "Washington"
        },
        {
          "city": "Port Angeles",
          "state": "Washington"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00217386"
    }
  ]
}